Richard P Slaughter Associates Inc Sells 208 Shares of Johnson & Johnson (NYSE:JNJ)

Richard P Slaughter Associates Inc trimmed its position in Johnson & Johnson (NYSE:JNJ) by 1.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,782 shares of the company’s stock after selling 208 shares during the quarter. Richard P Slaughter Associates Inc’s holdings in Johnson & Johnson were worth $1,559,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. Thurston Springer Miller Herd & Titak Inc. increased its holdings in Johnson & Johnson by 35.2% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 17,888 shares of the company’s stock valued at $2,587,000 after purchasing an additional 4,661 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of Johnson & Johnson by 942.2% during the fourth quarter. Assenagon Asset Management S.A. now owns 911,704 shares of the company’s stock valued at $131,851,000 after buying an additional 824,228 shares during the period. Board of the Pension Protection Fund bought a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $130,000. Allen Mooney & Barnes Investment Advisors LLC lifted its stake in Johnson & Johnson by 1.3% in the fourth quarter. Allen Mooney & Barnes Investment Advisors LLC now owns 8,283 shares of the company’s stock worth $1,198,000 after acquiring an additional 106 shares during the period. Finally, Fifth Third Wealth Advisors LLC boosted its holdings in Johnson & Johnson by 9.1% in the fourth quarter. Fifth Third Wealth Advisors LLC now owns 21,575 shares of the company’s stock valued at $3,120,000 after acquiring an additional 1,800 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $144.74 on Thursday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company has a market capitalization of $348.48 billion, a price-to-earnings ratio of 20.95, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company’s 50-day moving average is $149.12 and its 200 day moving average is $156.09.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.66 earnings per share. Sell-side analysts expect that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.43%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Wall Street Analyst Weigh In

JNJ has been the subject of several research analyst reports. StockNews.com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 7th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Wells Fargo & Company upped their target price on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, Wolfe Research started coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target on the stock. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $174.71.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.